Medpace Holdings, Inc. (NASDAQ:MEDP) Receives $469.50 Consensus PT from Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has been given an average rating of “Hold” by the fifteen ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $469.50.

A number of equities analysts have recently commented on MEDP shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. BMO Capital Markets dropped their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research report on Friday, April 24th. Mizuho raised their price target on shares of Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Royal Bank Of Canada decreased their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th.

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Medpace by 205.8% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. Franklin Resources Inc. boosted its stake in Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after purchasing an additional 183,645 shares in the last quarter. Norges Bank acquired a new position in Medpace in the fourth quarter worth $102,156,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Medpace by 92.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 347,049 shares of the company’s stock worth $194,920,000 after purchasing an additional 166,654 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 0.0%

Shares of NASDAQ:MEDP opened at $537.73 on Thursday. Medpace has a 1-year low of $306.70 and a 1-year high of $628.92. The firm has a market capitalization of $15.36 billion, a PE ratio of 33.80, a PEG ratio of 2.69 and a beta of 1.15. The business’s 50 day moving average is $478.10 and its 200-day moving average is $494.76.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.Medpace’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the company posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts predict that Medpace will post 17.04 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.